Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 525 followers
Latest posts
Last updated 1 day ago
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
1 day ago
Agreement allows manufacturers to develop, manufacture and supply generic LA injectable cabotegravir...
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
1 day ago
Multiple real-world studies show consistent high effectiveness of Vocabria + Rekambys across...
US FDA accepts application to review expanded use of GSK’s RSV vaccine, Arexvy, for adults 18-49 at increased risk
1 day ago
More than 21 million US adults under the age of 50 have...
ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025
7 days ago
Real-world and implementation data describe effectiveness of long-acting Vocabria + Rekambys (CAB+RPV...
GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
8 days ago
GSK plc today announced the completion of its previously announced acquisition of...
Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5
21 days ago
Price reduction is commitment by Bharat Biotech made possible through partnership with...
Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
22 days ago
Submission based on data from positive GLISTEN phase III trial
Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease
25 days ago
If approved, GSK’s RSV vaccine would be the first available in Japan...
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older
about 1 month ago
Regulatory decision anticipated H1 2026.
GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development
about 1 month ago
GSK plc announced today that it has licensed its Shigella vaccine candidate...
Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
about 1 month ago
Application based on data from positive GLISTEN phase III trial
GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio
about 2 months ago
GSK today announced that data across the oncology pipeline and portfolio will...